We describe a determination of zomepirac concentration in plasma and serum by reversed-phase "high-performance" liquid chromatography.'The assay requires 1.0 mL of sample and involves diethyl ether extraction of zomepirac from an acidified sample, followed by concentration and injection into a liquid chromatograph. The column effluent is monitored at 330 nm. Retention times of zomepirac and the internal standard (tolmetin) are 3.8 and 2.7 mm, respectively. The lower limit of detection for zomepirac in serum or plasma is 0.05 mg/L. Within-day precision (CV) of analysis in plasma or serum with zomepirac added (0.1-10.0 mg/L) ranged from 1.4 to 6.7%; between-day CV varied from 1.4 to 7.5%. Analytical recovery of zomepirac (1.0 mg/L) from serum and plasma was 77.6 (SD 3.5)% and 80.4 (SD 5.2)%, respectively. Numerous commonly coadministered drugs did not interfere. The elimination half-life of the drug was 1.8 h, and the peak plasma concentration ranged from 1.1 to 2.4 mg/L. Peak and trough concentrations measured throughout five days of therapy imply no accumulation.
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To minimize variations produced by sample extraction and chromatography, we included an internal standard in each sample. We used tolmetin as the internal standard because it is available commercially, is quite similar in structure to zomepirac (Figure 1) , and, like zomepirac, absorbs strongly at 330 nm. In addition, the retention time of tolmetin on a reversed-phase column is reasonably close to that of zomepirac.
We find that a mobile phase consisting of acetonitrile and potassium dihydrogen phosphate (0.1 molfL, pH 4.0) can be used for liquid-chromatographic analysis for a number of drugs besides zomepirac by adjusting the relative percentages of its two components. Figure 2A shows a typical chromatogram of pooled plasma from zomepirac-free volunteers. Figure   2B shows the chromatogram of a plasma sample from a pa- Chromatograms of either serum or the corresponding plasma were identical, and zomepirac and tolmetin were well resolved from other endogenous constitutents of the samples. Figure 3 shows results of analytical-recovery studies, in which zomepirac was added to plasma and serum to give concentrations of 0.1-10.0 mg/L, to bracket concentrations attained therapeutically (17, 18) . A linear and superimposable relation (r >0.99) between peak height and concentration was obtained for both serum and plasma over this range of zomepirac concentration. The practical limit of detection for plasma or serum zomepirac in our assay system was about 0.05 mg/L (at which signal/noise ratio = 3/1). The standard curve was linear from 0.05 to 50 mgfL.
To determine the precision of the assay, we added zomepirac to drug-free plasma and serum to yield concentrations of 0.1,1.0, and 10.0 mg/L. Within-day precision was determined by assaying these plasma and serum zomepirac concentrations 10 times on the same day. Between-day precision was measured by assaying one plasma and one serum sample of zomepirac daily for 10 days (Table 1) . Analytical recovery for zomepirac was determined by comparing the peak height produced by a known amount of zomepirac added to zomepirac-free plasma (or serum) pool (then extracted and chromatographed as described above) with the peak height of a known amount of zomepirac directly injected on the liquid chromatograph (Table 1 ). The absolute recovery of zomepirac from serum was not statistically different from that for plasma, except for a small difference at low concentration (0.1 mgfL). The reason for this small difference is not apparent.
The analytical recovery of tolmetin from serum and plasma was determined at a 1.0 mg/L concentration (Table 1) . We added several drugs ( 120 mm. After a rapid redistribution phase, the average single-dose plasma elimination half-life was 1.8 h (range, 1.5 to 2.2 h). These data are consistent with the two-compartment distribution/elimination model of drug clearance. Three of the volunteers continued taking Zomax, 100 mg every 6 h for five days. "Trough" specimens were collected each day, immediately before the next dose, and specimens for peak plasma concentrations of the drug were collected 30 to 120 mm after dosing, the time for each volunteer being based on the time of the peak on the first day. Trough and peak plasma zomepirac concentrations on days two through five ranged from 0.14 to 0.31 mg/L and 1.1 to 2.4 mg/L, respectively. Zomepirac did not accumulate in the plasma of any of the volunteers during the five-day dosage regimen, which is consistent with the observed short elimination half-life. The results of this brief study are not completely in agreement with the findings of Nayak et al. (17) , who reported peak plasma concentrations of approximately 4 mgfL within 1 to 2 h after a 100-mg oral dose of zomepirac, with art elimination half-life of approximately 4 h; the reasons for these differences are not apparent.
